Wells Fargo Maintains Overweight on RxSight, Raises Price Target to $68
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on RxSight (NASDAQ:RXST) and raises the price target from $61 to $68.
May 07, 2024 | 4:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wells Fargo analyst Larry Biegelsen maintains an Overweight rating on RxSight and raises the price target from $61 to $68.
The upgrade in price target by a reputable analyst like Larry Biegelsen suggests a strong bullish sentiment towards RxSight. This is likely to positively influence investor perception and could lead to a short-term increase in the stock price, as market participants often react to analyst ratings and price target adjustments.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100